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CLINICAL REPORT

Cutaneous Myeloid Sarcoma: Natural History and Biology of an
Uncommon Manifestation of Acute Myeloid Leukemia
M. Yadira Hurley1, Grant K. Ghahramani1, Stephanie Frisch1, Eric S. Armbrecht2, Anne C. Lind3, TuDung T. Nguyen3,
Anjum Hassan3, Friederike H. Kreisel3 and John L. Frater3

Department of Dermatology, 2School of Public Health, Saint Louis University, St. Louis, and 3Department of Pathology and Immunology, Washington
University, St. Louis, USA
1

We conducted a retrospective study of patients with cutaneous myeloid sarcoma, from 2 tertiary care institutions.
Eighty-three patients presented, with a mean age of 52
years. Diagnosis of myeloid sarcoma in the skin was difficult due to the low frequency of myeloperoxidase and/or
CD34+ cases (56% and 19% of tested cases, respectively).
Seventy-one of the 83 patients (86%) had ≥ 1 bone marrow biopsy. Twenty-eight (39%) had acute myeloid leukemia with monocytic differentiation. Twenty-three had
other de novo acute myeloid leukemia subtypes. Thirteen
patients had other myeloid neoplasms, of which 4 ultimately progressed to an acute myeloid leukemia. Seven had
no bone marrow malignancy. Ninety-eight percent of
the patients received chemotherapy, and approximately
89% died of causes related to their disease. Cutaneous
myeloid sarcoma in most cases represents an aggressive
manifestation of acute myeloid leukemia. Diagnosis can
be challenging due to lack of myeloblast-associated antigen expression in many cases, and difficulty in distinguishing monocyte-lineage blasts from neoplastic and
non-neoplastic mature monocytes. Key words: cutaneous
myeloid sarcoma; chloroma; myeloid sarcoma; mono
blastic sarcoma.
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The World Health Organization defines myeloid sarcoma
as “a tumor mass consisting of myeloid blasts with or
without maturation occurring at an anatomical site other
than the bone marrow” (1). Although the skin is identified
as a common site of involvement of myeloid sarcoma,
studies of cutaneous myeloid sarcoma (CMS) are relatively lacking. A large study consisting of cases presenting
in the skin is desirable to evaluate the demographic,
clinical, and histopathologic properties of CMS, and the
potential impact of the microanatomy and cytokine milieu
of the skin in the presentation of cutaneous leukemias.
© 2013 The Authors. doi: 10.2340/00015555-1458
Journal Compilation © 2013 Acta Dermato-Venereologica. ISSN 0001-5555

We report the results of a retrospective study of 83
patients presenting with CMS over a 19-year period at
2 tertiary care institutions in the Midwest United States.
We emphasize the demographics, clinical presentation,
and pathologic workup of these patients, and their response to therapy.
METHODS
The study was performed with the joint approval of the Institutional Review Boards of the Saint Louis University and
Washington University Schools of Medicine.
Search parameters
A search of the electronic databases of the Department of
Dermatology, Division of Dermatopathology, Saint Louis
University, and the Section of Anatomic and Molecular Pathology, Department of Pathology and Immunology, Washington
University, was performed. Typical patient demographic data
was collected (date of birth, gender, and race) along with dermatological information regarding lesion size, morphology, and
anatomic site. In addition, data concerning other anatomic sites
of involvement, patient treatment regimen, clinical course, and
survival status were also recorded.
The study also describes the bone marrow in comparison
with the cutaneous involvement of myeloid blasts. This was
accomplished by including bone marrow aspirate immunohisto
chemistry, histochemistry, flow cytometry, phenotype of the
myeloid leukemia by flow cytometry, marrow cellularity,
myeloid:erythroid ratio, myeloid blast cell percentage, along
with enzyme cytochemical analysis results. Whenever available,
karyotype, fluorescence-in-situ-hybridization, and the results
of molecular genetic testing were also included.
Chart review
The charts of all patients were reviewed for evaluation of the
following parameters: age at initial presentation, gender, race,
site(s) of involvement, clinical description of lesion(s), temporal
relationship of CMS to acute myeloid leukemia (AML) (i.e. did
the diagnosis of CMS precede, coincide, or follow the diagnosis
of AML), therapy, and outcome. For patients who were evaluated at Saint Louis University or Washington University and
treated elsewhere, additional clinical follow-up was obtained
from the referring clinicians.
Pathologic review
In all patients, the diagnostic biopsies of the skin, bone marrow,
and other sites of involvement were reviewed for all available
cases. Notes were made of the histopathologic features, immunohistochemistry, and flow cytometry of all tested cases.
Acta Derm Venereol 93
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Statistical analysis
The patient demographics, cutaneous lesion presentation
characteristics, dermatopathologic findings, and bone marrow
characteristics of patients with CMS were described using
frequencies (%) for categorical level variables and measures
of central tendency (means ± standard deviation (SD)) for continuous level variables.
Additionally comparisons were made to identify if the characteristics vary between length of time from diagnosis of AML,
age, race, site of involvement, number of lesions, and other
important factors. Chi-square analysis, independent samples
t-test, and analysis of variance between groups (ANOVA)
were utilized to analyze the data. All analyses were defined as
statistically significant when α < 0.05. SPSS software, version
16 (Chicago, Illinois) was used for the analysis.

RESULTS
Eighty-three patients were identified in the search of
the laboratory information systems of both institutions.
Although CMS has a male predominance (50 males
and 33 females, p = 0.62). The vast majority of patients
were white (86% of patients), and a wide age range
was identified, with age at onset of cutaneous disease
range between 2 weeks–89 years old. The lesions were
discrete in all cases, and most often were described
as papules, nodules, or plaques. They presented most
commonly on the torso (39% of cases), followed by the
upper extremities (24%), lower extremities (21%), and
head and neck (16%). In 34 cases the patients had a
diagnosis of bone marrow-based AML and a sufficient
clinical history allowed a temporal relationship to be
established between the two diagnoses. CMS preceded
the bone marrow diagnosis of AML in 6 (18 %) cases,
followed it in 15 (44%), and was coincident with the
diagnosis of AML in the bone marrow (defined as occurring within 2 weeks of the bone marrow diagnosis)
in 13 (38%). Most patients had disease limited to the
skin and bone marrow; however, 18/83 (22%) of the
patients experienced involvement of sites outside the
skin and bone marrow, most commonly the central nervous system (6 cases) and lymph nodes (6 cases). Other
sites of involvement included the gastrointestinal tract,
liver, and lung (3 patients each), and the spleen, oral
mucosa, and testes (2 patients each). Fifteen patients
had involvement of the bone marrow by an AML with
monocytic differentiation (French-American-British
classification of AML (FAB): M4 or M5). Using the
“registry” with 83 cases of CMS, the one-year mortality
status was determined for 59 (or 71.1%) of cases. Of
these 59 cases, 86.4% were deceased one-year after
the diagnosis date. Of the patients who died during
the observed period, the mean number of survival days
after the diagnosis date was 227 ± 319 (range 14–1,561,
median  64, 25–75% 31–275). The death date was unknown for one of the 51 cases known to be deceased.
The mean age at CMS diagnosis was 54.9 ± 20 years,
based on 75 cases with known age at CMS diagnosis.
Acta Derm Venereol 93

Women were younger than men at age of diagnosis
(49.5 vs 58.4), but this was not statistically significant
(p = 0.062). No difference was observed in age at diagnosis by race (white vs. black vs. other). The possible association between patient age at diagnosis and
survival days was explored by calculating the Pearson
correlation coefficient. Among the 51 patients who
were deceased, there was no correlation between age
at diagnosis and survival days (correlation coefficient
of 0.012, p = 0.993). The registry includes 18 cases who
survived for > 1 year. Among these 18 cases, the mean
age at diagnosis was 51.6 ± 22 among the 17 subjects
with known age information. 61% of survivors were
male; 61% were Caucasian. There was no statistically
significant difference between mean age at diagnosis
(p = 0.352) or gender (p = 0.800) between one-year
survivors and deceased cases. When examined for survival at the 60-day mark, the same results persisted: no
differences were seen between mean age at diagnosis
or gender. Four patients were autopsied, all of whom
had noncutaneous sites of involvement which had not
been detected antemortem.
The skin lesions had a variable microscopic appearance. The overlying epidermis was essentially unremarkable in all cases. In all cases the malignant cells involved
the superficial and deep dermis. The cells comprising the
infiltrate were clearly identifiable as blasts in most cases
by their immature cytomorphology, abundant mitotic
activity, dispersed nuclear chromatin with nucleoli, and
scattered apoptotic cells. This cytomorphology was a
particularly important consideration for cases in which
the infiltrate was relatively subtle and/or predominantly
perivascular and could simulate a benign process inflammatory skin disorder. Eleven cases demonstrated
extension of blasts through the dermis into the underlying subcutis. In most cases the pattern of infiltration
was perivascular, periadnexal, and interstitial, with
relative preservation of the microanatomy of the dermis
(Fig. 1). In contrast, 20 cases demonstrated an overall
pattern of diffuse involvement, with destruction of the
normal microanatomic features of the dermis (Fig. 2).
In a statistical comparison of cases with diffuse growth
versus others, there were no significant differences regarding survival, and the demographic and phenotypic
properties of both groups were similar.
Due to the retrospective nature of this study, in which
the cases were initially reviewed by a large number
of hematopathologists and dermatopathologists, the
diagnostic approach to the skin biopsies was highly
variable. The myeloid lineage of all cases was subsequently established by us (2). Cases initially presenting
in the bone marrow with secondary involvement of
the skin frequently had a minimal workup, since the
differential diagnosis was very limited. Nineteen cases
with involved skin biopsies and a prior bone marrow
diagnosis of AML were evaluated by a hematoxylin
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CD34 (3/16, 19%). A comprehensive list
of antibodies reviewed in this study is
listed in Table SI (available from http://
www.medicaljournals.se/acta/content/?d
oi=10.2340/00015555-1458). Of note, several cases demonstrated aberrant expression of markers of other lineages, which
is a well-known phenomenon in AML
but may lead to an erroneous diagnosis,
particularly in patients with a limited
immunohistochemical workup and/or
lack of clinical history. Aberrant expression of B-lymphoid-related antigens was
rare, limited to CD20 expression in one
of 20 tested cases. This unusual finding
has been previously noted in AML (3)
Aberrant expression of T- and NK-cell
antigens was more frequent. CD5 expression was noted in 1 of 2 tested cases,
which has been reported in rare cases
of AML (4). CD7 was positive in 1 of 5
tested cases; however the diagnosis of
T-cell lymphoma was not of diagnostic
concern based on the absence of expression of other T-cell associated antigens,
and the supporting clinical history. CD56
Fig. 1. Myeloid sarcoma, example of a case (A) with focal architecture, characterized by
was expressed in 5 of 6 tested cases,
periadnexal, perivascular, and perifollicular growth with sparing of dermal microanatomic
and in 3 of these cases was coexpressed
structures, and (B) extension into the subcutaneous fat (H&E, original magnifications ×200).
with CD4 (Fig. S1; available from http://
(C, D) Blasts are large with high nuclear: cytoplasmic ratio, dispersed nuclear chromatin, and
prominent nucleoli; mitoses are prominent (H&E, original magnification ×400).
www.medicaljournals.se/acta/content/?
doi=10.2340/00015555-1458). The differential diagnosis for such cases, partiand eosin-stained section without additional studies. In
cularly in patients presenting with skin lesions, includes
an additional 19 patients, evaluated by a hematoxylin
blastic plasmacytoid dendritic cell neoplasm (formerly
and eosin-stained section and a chloroacetate esterase
referred to as blastic natural killer cell lymphoma and
(Leder) stained section, the blasts were Leder negaagranular CD4+/CD56+ hematodermic neoplasm). In
tive. The remaining cases had immunohistochemistry
such patients, a more extensive immunohistochemical
analysis as part of their workup, including lysozyme
workup may be warranted, and the clinical history may
(positive in 14/14[100%] of tested cases), myelobe critical. All 3 patients with CD4+/CD56+ blasts had
peroxidase (20/36, 56%), CD68 (14/14, 100%), and
a prior history of AML (2 with acute myelomonocytic

Fig. 2. Myeloid sarcoma; example of a
case with diffuse growth, characterized
by destruction of dermal microanatomic
structures (hematoxylin and eosin,
original magnifications × 200, × 400).
Leder histochemistry is negative
in blasts (original magnification
× 400). Immunohistochemistry (× 400)
demonstrates the blasts to express CD7,
CD117, and CD34 (partial).
Acta Derm Venereol 93
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leukemia, one with relapsed acute AML in which the
original material could not be reviewed) and had blasts
which also expressed lysozyme and CD68. Although
rare CD68+ cases of blastic plasmacytoid dendritic cell
neoplasm have been reported in the literature, lysozyme
expression is indicative of myeloid origin for the malignant cells.
Of the 83 patients 71 (85%) had at least one bone
marrow biopsy available for review. Twenty-nine patients (41%) had an AML with monocytic differentiation
(15 acute myelomonocytic leukemias [FAB: M4], 14
acute monoblastic/ monocytic leukemias [FAB: M5]).
Thirty-five patients had other AML subtypes. Many
AML cases could not be further subclassified because
1) a disease-defining cytogenetic abnormality was not
present and 2) enzyme cytochemical analysis of the
blasts was not performed. Thirteen patients had myeloproliferative neoplasms, myelodysplastic syndromes, or
overlap diseases (5 cases of chronic myelomonocytic
leukemia), of which 5 ultimately progressed to an
AML Seven patients had no evidence of bone marrow
involvement by a malignancy. A comprehensive list of
bone marrow diagnoses is listed in Table II (available
from http://www.medicaljournals.se/acta/content/?d
oi=10.2340/00015555-1458). Cytogenetic and/or molecular genetic results were abnormal in 23/29 (79%) of
tested individuals and revealed the following: 2 patients
with loss of chromosome 7, 2 patients with loss of the
long arm of chromosome 7, 7 patients with trisomy of
chromosome 8, and 5 patients with abnormalities of
chromosome 11q23 involving the mixed lineage leukemia
(MLL) locus. Nine patients had multiple nonspecific
structural and/or numerical chromosomal abnormalities. Five patients had normal conventional cytogenetic
analysis. Fluorescence in situ-hybridization confirmed
the findings of MLL rearrangement in 4 patients and
trisomy of chromosome 8 in 4 patients, and revealed
low-level abnormal loss of the RUNX1 (formerly known
as AML1) locus in one patient with normal conventional
cytogenetics.
Due to the retrospective nature of the specimens,
analysis of the degree of phenotypic concordance between the skin and bone marrow specimens is limited.
However, the available data support that the blast immunophenotype is retained at both sites (Tables I and
II), both in cases with flow cytometric analysis of the
bone marrow and in cases with immunohistochemical
analysis of the bone marrow. In addition, there was only
one case with discordant CD117 immunohistochemistry,
a case of AML derived from prior chronic myelomonocytic leukemia.
DISCUSSION
The skin is one of the most common sites of involvement
by myeloid sarcoma. The mechanism responsible for the
Acta Derm Venereol 93

Table I. Reactivity for selected immunohistochemistry in skin
biopsies by bone marrow diagnostic group
Lysozyme

Myeloperoxidase

CD68

Diagnosis

Positive Negative Positive Negative Positive Negative

M0
M1
M2
M4
M5
M7
CMML
MDS
JMML
Unknown
Unclassifiable
Total

0
1
2
5
3
0
3
1
1
12
0
28

0
0
0
0
0
0
0
0
0
1
0
1

0
1
0
3
1
0
2
3
1
8
0
19

1
0
0
4
3
1
0
0
0
5
3
17

0
0
0
2
2
0
1
0
0
9
0
14

0
0
0
0
0
0
0
0
0
0
0
0

CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic
syndrome; JMML: juvenile myelomonocytic leukemia.

migration of myeloid blasts to the skin is poorly understood, but is hypothesized to be the result of the expression of chemokine receptors and adhesion molecules by
the blasts and various cell types residing in the skin (5).
The mechanism of preferential migration of blasts to the
skin rather than to other extramedullary sites is likewise
Table II. Concordance between skin and bone marrow blast
phenotypes
Antibody

Bone marrow
diagnosis

Skin result

Bone marrow
result

Concordant skin immunohistochemistry/bone marrow flow cytometry
CD4
M4
+
+
CD4
M4
+
+
CD5
M4
+
+
CD33
M5
+
+
CD34
M4
–
–
CD34
M4
–
–
CD34
M5
+
+
CD34
M5
–
–
CD34
M4
+
+
CD56
M5
+
+
CD56
M4
+
+
CD56
M4
+
+
CD117
M4
+
+
CD117
M0
–
–
Discordant skin immunohistochemistry/bone marrow flow cytometry
CD4
M4
+
–
CD34
AML ex CMML
–
+
CD34
M6a
–
+
CD117
AML ex CMML
–
+
Concordant skin immunohistochemistry/bone marrow immunohistochemistry
CD3
M4
–
–
CD4
M4
+
+
CD7
M4
–
–
CD8
M4
–
–
CD20
M4
–
–
CD30
M4
–
–
CD34
M4
–
–
CD34
AML NOS
–
–
CD56
M4
+
+
CD56
M5
+
+
CD68
M2
+
+
AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia;
NOS: nitric oxide synthase.
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unknown, but may be related to the similarity of certain
features of the microanatomies of both sites, such as the
rich microvascular background and similar percentage
of type III collagen and other intermediate filaments.
Despite the frequency of involvement of the skin by
AML, large studies of CMS are relatively few. To our
knowledge, 9 previous studies have appeared in the peer-reviewed English language medical literature within
the last 20 years (6–14), none of which fully address all
major questions regarding clinical and pathologic features, molecular genetic findings, and outcome in CMS.
In our study, CMS is identified as predominantly
affecting the elderly, although a broad age range is
present. This is also reflected in the medical literature
(6–14). Like us, most series reported a male predominance, although the study of Kaddu et al. (11) reports
a predominance of females. Information about risk of
cutaneous disease based on ethnicity is relatively lacking, probably due to a relative paucity of cases reported
from North America. In our study, the vast majority of
patients were Caucasian. Lesions are usually multiple
and are described as papules, plaques, and/or nodules.
The torso is most commonly involved, although a wide
range of body sites has been reported. Our data show
that the distribution of lesions favors the upper body.
In all series in which an appropriate level of detail
was provided (7–14), the most common bone marrow
diagnosis was AML, and cases with myelomonocytic
or monoblastic/monocytic differentiation were prominently represented. When reported, CMS was noted to
follow the initial bone marrow diagnosis (6, 12, 13),
though most patients eventually have bone marrow
involvement. The pattern of skin involvement has been
described previously (8, 9, 11–13), and Benet et al.
(13) describe that cases initially presenting in the skin
have a predilection for diffuse architecture, “high dense
infiltrate”, large cells, and high mitotic index compared
to cases with secondary involvement of the skin. This
finding was not observed in our cases. The reason for
this is uncertain, but may involve timing of the biopsy
(longer-standing lesions would presumably have a larger
number of malignant cells), preferential biopsy of the
center vs. the leading edge of a lesion, or some other factor. Moreover, the clinical significance of differentiating
the de novo vs. secondary cases (which could, of course,
have been resolved on clinical grounds) is likely of little
consequence in our patients, since survival for patients
in our series was almost uniformly poor; patients do not
appear to have benefitted from recent innovations in
chemotherapeutic regimens or bone marrow transplant,
as previous studies performed over a decade ago have
demonstrated similar findings (8, 11).
Genetic mutations are not widely reported in cases
of AML with skin involvement, and are postulated
to be similar to the commonly occurring cytogenetic
findings in AMLs occurring in other sites. Notably, a
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high percentage of cases in our series had abnormal conventional cytogenetic findings. In 25% of cases, there
were multiple numerical and/or structural abnormalities,
suggestive of evolution of an aggressive clone. Of the
cases, 25% had trisomy of chromosome 8, a finding
identified in myeloid sarcomas involving the skin (14)
and other sites.
Numerous studies emphasize the challenges in diagnosing CMS. In large part, this is due to the historic
and ongoing problems in distinguishing non-neoplastic
from neoplastic monocytes and their precursors and the
relative insensitivity of antibodies such as CD34 and
CD117 in identifying blasts in the skin. These are, of
course, related concepts, since the highest percentage
of cases in all studies, including ours, represent involvement of the skin by AML with monocytic differentiation, either acute myelomonocytic leukemia (FAB:
M4) or acute monoblastic/monocytic leukemia (FAB:
M5). It is thus important to identify a battery of immunohistochemical markers which distinguish AMLs
involving the skin from other diseases. In addition,
it may be of interest to identify those markers which
successfully identify cases with monocytic differentiation, for several reasons: patients with acute monocytic
leukemia may have a more aggressive disease course,
although this is controversial and not uniformly seen
in all studies (15–19); AMLs with monocytic differentiation may harbor rearrangements involving the MLL
gene, many of which, with the prominent exception of
the translocation t (9;11), have been associated with a
more aggressive disease course; and perhaps most importantly for diagnostic purposes, it may be important
to the diagnostician to determine if reactivity for a given
marker is sufficiently specific to identify cases having
monocytic differentiation.
In our patients, the antibodies which were most sensitive in detecting cases of CMS, but were unhelpful
in distinguishing AMLs with monocytic differentiation
from others and were performed in a sufficient number
of cases to be assessed were CD43, CD68, and lysozyme. CD43, although highly sensitive, has a broad
range of expression, including granulocytes, T cells,
and some malignant B cells (20). Lysozyme, although
very sensitive for the detection of myeloid disease, is
relatively nonspecific for distinction of malignancies
with monocytic differentiation (e.g. M4, M5, chronic myelomonocytic leukemia (CMML)) from other
leukemias without monocytic differentiation (e.g.M1,
M2). Myeloperoxidase is frequently negative due to
the high frequency of AML with monocytic differentiation. CD68 is reportedly similar to lysozyme in sensitivity, and is similarly nonspecific for distinction of
malignancies with monocytic differentiation (e.g. M4,
M5 CMML) from other leukemias without monocytic
differentiation (e.g.M1, M2). We conclude that none
of the antibodies studied by us is sufficiently specific,
Acta Derm Venereol 93
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either alone or in combination, to distinguish AMLs with
monocytic differentiation from other AMLs, although
CD43, lysozyme, and CD68 are most sensitive in differentiating CMS from other disorders.
Also of interest is whether the blast phenotype is
concordant between the bone marrow and skin populations, or whether there is a high rate of phenotypic
discordance, as has been previously reported (14).
Notably, the earlier study of Cronin et al. (14) does not
include bone marrow immunohistochemistry, which
was often employed in our cases in lieu of or in addition to flow cytometry. Due to the retrospective nature
of this study, complete and uniform immunophenotypic analysis of all cases was not performed. However,
our data show that the blast phenotype as assessed by
immunohistochemistry is highly consistent between
sites. Four discordant cases were identified by flow
cytometry comparing flow cytometry of the bone marrow and immunohistochemistry of the skin. These
differences thus may more likely represent differences
in the techniques such as antibody sensitivities rather
than a true discrepant phenotype between the skin and
bone marrow blasts.
To summarize, CMS is an uncommon malignancy
which in most cases represents an aggressive manifestation of AML. Diagnosis can be challenging due to the
lack of myeloblast-associated antigen expression in
many cases, and the difficulty in distinguishing monocyte-lineage blasts from neoplastic and non-neoplastic
mature monocytes, and aberrant expression of CD7
and/ or CD56. However, the combination of highly
sensitive (CD43 and lysozyme) and more specific (myeloperoxidase, CD68, CD117, and CD34) antibodies
can aide in the identification of suspected cases. There
are additional antibodies that are more specific and
sensitive for use in the setting of a suspected CMS (2).
Interestingly, the blast phenotype is usually concordant
between the bone marrow and skin populations. Cytogenetic abnormalities were detected in a high percentage
of cases, consistent with the aggressive behavior of this
disease. The vast majority of patients died of disease
within one year of diagnosis. As the clinical data show,
the majority of patients with this disorder have a prior
or concomitant history of AML. Thus, diagnosis of
CMS is multidisciplinary in many cases and is greatly
facilitated by the clinical history.
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